Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab for Behçet's Disease Resistant to Standard Treatment
2010-024152-29Phase 3Completed
- Sponsor
- University Hospital Tübingen
- Start
- Jun 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, single-arm trial of canakinumab in Behçet's disease (BD), sponsored by University Hospital Tübingen. Primary endpoints: Change in Behçet's Disease Current Activity Form (BDCAF) and Change in uveitis activity score. Started Jun 2011; status: completed.
02
Drugs
canakinumab
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on 2010-024152-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024152-29.